Outcomes of Patients With Long-Term Treatment Response to
Vascular Endothelial Growth Factor-Targeted Therapy for
Metastatic Renal Cell Cancer

J 2017

Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer

BUCHLER, T., Alexandr POPRACH, Zbyněk BORTLÍČEK, Radek LAKOMÝ, Renata CHLOUPKOVÁ et. al.

Základní údaje

Originální název

Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer

Autoři

BUCHLER, T. (203 Česká republika), Alexandr POPRACH (203 Česká republika, domácí), Zbyněk BORTLÍČEK (203 Česká republika, garant, domácí), Radek LAKOMÝ (203 Česká republika, domácí), Renata CHLOUPKOVÁ (203 Česká republika, domácí), Rostislav VYZULA (203 Česká republika, domácí), M. ZEMANOVA (203 Česká republika), K. KOPECKOVA (203 Česká republika), Marek SVOBODA (203 Česká republika, domácí), Ondřej SLABÝ (203 Česká republika, domácí), Igor KISS (203 Česká republika, domácí), H. STUDENTOVA (203 Česká republika), J. HORNOVA (203 Česká republika), O. FIALA (203 Česká republika), J. KOPECKY (203 Česká republika), J. FINEK (203 Česká republika), Ladislav DUŠEK (203 Česká republika, domácí) a B. MELICHAR (203 Česká republika)

Vydání

CLINICAL GENITOURINARY CANCER, DALLAS, CIG MEDIA GROUP, LP, 2017, 1558-7673

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.539

Kód RIV

RIV/00216224:14110/17:00095683

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.clgc.2017.06.006

UT WoS

000417112200017

Klíčová slova anglicky

Pazopanib; Renal cell carcinoma; Sorafenib; Sunitinib; Survival

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 21. 3. 2018 16:23, Soňa Böhmová

Anotace

V originále

Although targeted therapies are the mainstay of treatment for metastatic renal cell carcinoma there are limited data on the outcomes of patients with long-term responses. We report the outcomes of a registry-based study of patients continuously treated with first-line targeted therapy for at least 24 months. There were clinically important differences in survival between patients who achieved complete response and those with partial response or stable disease. These differences had not been described before and are important for treatment optimization of this patient subgroup. Background: Although targeted therapies with inhibitors of the vascular endothelial growth factor (VEGF) are the mainstay of treatment for metastatic renal cell carcinoma, there are limited data on the outcome of patients with long-term response to this treatment. Patients and Methods: In a retrospective, registry-based study, patients continuously treated with first-line anti-VEGF agents for at least 24 months were included. In total, 219 patients had evaluable data and were included in the outcome analysis. Results: Median progression-free survival (PFS) after initiation of first-line targeted therapy was 39.7 months (95% confidence interval [CI], 35.9-43.5 months), with 5-year PFS of 34.2% (95% CI, 27.2%-41.2%). Median overall survival (OS) reached 79.1 months (95% CI, 65.2-93.0 months) with the 5-year OS of 62.1% (95% CI, 54.5%-69.7%). In this cohort, 28, 103, and 88 patients achieved complete response (CR), partial response (PR), or stable disease (SD) as the best response, respectively. Median PFS and OS were comparable in patients with PR and SD, but significantly longer in patients with CR (log rank test P value for PFS difference <.001 and.009 for OS difference). Conclusion: There are marked differences in PFS and OS between patients who receive long-term anti-VEGF treatment, achieving CR and non-CR as the best clinical response. Patients with non-CR experienced a relatively high progression rate shortly after the landmark time point of 2 years. (C) 2017 Elsevier Inc. All rights reserved.

Návaznosti

NV15-34678A, projekt VaV

Název: Molekulární prognostické a prediktivní faktory u pacientů s metastatickým renálním karcinomem léčených tyrozinkinázovými inhibitory

Citovat

BUCHLER, T., Alexandr POPRACH, Zbyněk BORTLÍČEK, Radek LAKOMÝ, Renata CHLOUPKOVÁ, Rostislav VYZULA, M. ZEMANOVA, K. KOPECKOVA, Marek SVOBODA, Ondřej SLABÝ, Igor KISS, H. STUDENTOVA, J. HORNOVA, O. FIALA, J. KOPECKY, J. FINEK, Ladislav DUŠEK a B. MELICHAR. Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer. CLINICAL GENITOURINARY CANCER. DALLAS: CIG MEDIA GROUP, LP, 2017, roč. 15, č. 6, s. "E1047"-"E1053", 7 s. ISSN 1558-7673. Dostupné z: https://dx.doi.org/10.1016/j.clgc.2017.06.006.

@article{1399364,
   author = {Buchler, T. and Poprach, Alexandr and Bortlíček, Zbyněk and Lakomý, Radek and Chloupková, Renata and Vyzula, Rostislav and Zemanova, M. and Kopeckova, K. and Svoboda, Marek and Slabý, Ondřej and Kiss, Igor and Studentova, H. and Hornova, J. and Fiala, O. and Kopecky, J. and Finek, J. and Dušek, Ladislav and Melichar, B.},
   article_location = {DALLAS},
   article_number = {6},
   doi = {http://dx.doi.org/10.1016/j.clgc.2017.06.006},
   keywords = {Pazopanib; Renal cell carcinoma; Sorafenib; Sunitinib; Survival},
   language = {eng},
   issn = {1558-7673},
   journal = {CLINICAL GENITOURINARY CANCER},
   title = {Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer},
   volume = {15},
   year = {2017}
}

TY  - JOUR
ID  - 1399364
AU  - Buchler, T. - Poprach, Alexandr - Bortlíček, Zbyněk - Lakomý, Radek - Chloupková, Renata - Vyzula, Rostislav - Zemanova, M. - Kopeckova, K. - Svoboda, Marek - Slabý, Ondřej - Kiss, Igor - Studentova, H. - Hornova, J. - Fiala, O. - Kopecky, J. - Finek, J. - Dušek, Ladislav - Melichar, B.
PY  - 2017
TI  - Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer
JF  - CLINICAL GENITOURINARY CANCER
VL  - 15
IS  - 6
SP  - "E1047"-"E1053"
EP  - "E1047"-"E1053"
PB  - CIG MEDIA GROUP, LP
SN  - 15587673
KW  - Pazopanib
KW  - Renal cell carcinoma
KW  - Sorafenib
KW  - Sunitinib
KW  - Survival
N2  - Although targeted therapies are the mainstay of treatment for metastatic renal cell carcinoma there are limited data on the outcomes of patients with long-term responses. We report the outcomes of a registry-based study of patients continuously treated with first-line targeted therapy for at least 24 months. There were clinically important differences in survival between patients who achieved complete response and those with partial response or stable disease. These differences had not been described before and are important for treatment optimization of this patient subgroup. Background: Although targeted therapies with inhibitors of the vascular endothelial growth factor (VEGF) are the mainstay of treatment for metastatic renal cell carcinoma, there are limited data on the outcome of patients with long-term response to this treatment. Patients and Methods: In a retrospective, registry-based study, patients continuously treated with first-line anti-VEGF agents for at least 24 months were included. In total, 219 patients had evaluable data and were included in the outcome analysis. Results: Median progression-free survival (PFS) after initiation of first-line targeted therapy was 39.7 months (95% confidence interval [CI], 35.9-43.5 months), with 5-year PFS of 34.2% (95% CI, 27.2%-41.2%). Median overall survival (OS) reached 79.1 months (95% CI, 65.2-93.0 months) with the 5-year OS of 62.1% (95% CI, 54.5%-69.7%). In this cohort, 28, 103, and 88 patients achieved complete response (CR), partial response (PR), or stable disease (SD) as the best response, respectively. Median PFS and OS were comparable in patients with PR and SD, but significantly longer in patients with CR (log rank test P value for PFS difference <.001 and.009 for OS difference). Conclusion: There are marked differences in PFS and OS between patients who receive long-term anti-VEGF treatment, achieving CR and non-CR as the best clinical response. Patients with non-CR experienced a relatively high progression rate shortly after the landmark time point of 2 years. (C) 2017 Elsevier Inc. All rights reserved.
ER  -

BUCHLER, T., Alexandr POPRACH, Zbyněk BORTLÍČEK, Radek LAKOMÝ, Renata CHLOUPKOVÁ, Rostislav VYZULA, M. ZEMANOVA, K. KOPECKOVA, Marek SVOBODA, Ondřej SLABÝ, Igor KISS, H. STUDENTOVA, J. HORNOVA, O. FIALA, J. KOPECKY, J. FINEK, Ladislav DUŠEK a B. MELICHAR. Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer. \textit{CLINICAL GENITOURINARY CANCER}. DALLAS: CIG MEDIA GROUP, LP, 2017, roč.~15, č.~6, s.~''E1047''-''E1053'', 7 s. ISSN~1558-7673. Dostupné z: https://dx.doi.org/10.1016/j.clgc.2017.06.006.

Podrobný výpis o publikaci